From MarketBeat:

Thermo Fisher Scientific issued an update on its FY 2024 earnings guidance with EPS guidance of 20.950-22.000 and revenue guidance of $42.1 billion-$43.3 billion. Thermo Fisher Scientific stock opened at $566.94 on Wednesday with a market cap of $219.05 billion and a price-to-earnings-growth ratio of 3.35. The company also recently disclosed a quarterly dividend and authorized a share buyback program that allows the company to repurchase $4.00 billion in shares.

Thermo Fisher Scientific has been rated by multiple research reports, with a consensus rating of Moderate Buy and a consensus target price of $595.76. CEO Marc N. Casper recently sold 10,000 shares of the business’s stock at an average price of $456.15. A number of hedge funds have modified their holdings of the company, owning 87.06% of the stock.

Thermo Fisher Scientific provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines. They report $42.1 billion and $43.3 billion for their revenue guidance.



Read more: Thermo Fisher Scientific (NYSE:TMO) Issues FY 2024 Earnings Guidance